ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience
Sang Hyoung Park, Shin Kim, Ok Bae Ko, Ja Eun Koo, Danbi Lee, Yong Pil Jeong, Jooryung Huh, Sung-Bae Kim, Sang We Kim, Jae-Lyun Lee, Cheolwon Suh
Korean J Intern Med. 2006;21(3):159-164. Published online September 30, 2006
BackgroundThe ESHAP chemotherapy regimen, that is, the combination of the etoposide, methylprednisolone, high-dose cytarabine and cisplatin, has been shown to be active against relapsing or refractory non-Hodgkin's lymphoma (NHL) in previous therapeutic trials. We attempted to..
|